fenofibrate has been researched along with Retinal Diseases in 6 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 9.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 5.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "Fenofibrate treatment in type 2 diabetes patients reduces progression of diabetic retinopathy independent of its peroxisome proliferator-activated receptor (PPAR)α agonist lipid lowering effect." | 1.43 | Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. ( Burnim, SB; Edin, ML; Fu, Z; Gong, Y; Hellström, A; Liegl, RG; Lih, FB; Liu, CH; Meng, SS; SanGiovanni, JP; Shao, Z; Smith, LEH; Sun, Y; Wang, Z; Zeldin, DC, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Teoh, CS | 1 |
| Yuen, YS | 1 |
| Kataoka, SY | 1 |
| Lois, N | 1 |
| Kawano, S | 1 |
| Kataoka, Y | 1 |
| Inoue, K | 1 |
| Watanabe, N | 1 |
| Pearsall, EA | 1 |
| Cheng, R | 2 |
| Matsuzaki, S | 1 |
| Zhou, K | 1 |
| Ding, L | 2 |
| Ahn, B | 1 |
| Kinter, M | 1 |
| Humphries, KM | 1 |
| Quiambao, AB | 1 |
| Farjo, RA | 1 |
| Ma, JX | 2 |
| Moran, E | 1 |
| Wang, Z | 2 |
| Chen, Q | 1 |
| Moore, R | 1 |
| Takahashi, Y | 1 |
| Chahande, S | 1 |
| Murthy, R | 1 |
| Gong, Y | 1 |
| Shao, Z | 1 |
| Fu, Z | 1 |
| Edin, ML | 1 |
| Sun, Y | 1 |
| Liegl, RG | 1 |
| Liu, CH | 1 |
| Burnim, SB | 1 |
| Meng, SS | 1 |
| Lih, FB | 1 |
| SanGiovanni, JP | 1 |
| Zeldin, DC | 1 |
| Hellström, A | 1 |
| Smith, LEH | 1 |
1 review available for fenofibrate and Retinal Diseases
| Article | Year |
|---|---|
Fenofibrate for diabetic retinopathy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Mac | 2023 |
5 other studies available for fenofibrate and Retinal Diseases
| Article | Year |
|---|---|
Spectral-Domain OCT Imaging of Lipemia Retinalis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Diabetes Complications; Drug Therapy, Combinati | 2021 |
Neuroprotective effects of PPARα in retinopathy of type 1 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Disease Models, Animal; Fenofib | 2019 |
Protective and antioxidant effects of PPARα in the ischemic retina.
Topics: Animals; Animals, Newborn; Antioxidants; Apoptosis; Blotting, Western; Cells, Cultured; Disease Mode | 2014 |
Lipemia retinalis following systemic steroids for neurocysticercosis in a juvenile diabetic.
Topics: Adolescent; Anti-Inflammatory Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; | 2015 |
Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Choroidal Neovascularization; Cytochrome P-450 Enzyme Inhibitors; | 2016 |